Investment Q&A

Q: What are your thoughts on company at this time

Q: For a TFSA. any one of these preferable

Choosing only GUD a sound choice, if one wanted maximum result

Q: Hello, I would like to purchase has some more of these shares but am worried about the potential of the USA cross border tax and especially in the health care field. Do you believe CRH would be included in this tax and should I hold off and see what happens and how will I be able to tell when or if the tax will be imposed? Thanks for your insight.

Q: Hello,

I am selling my GILD stock today. what would you suggest as a replacment for this in the US.
Thank you

Q: what is going on with savaria down 2 days now buying opportunity ?

Q: Hi ,if you can clarify a scenario
- Using the finaning done by CVM.v as an example . They raised $12 million at .33 with a 1/2 warrant (full warrant exercise price .70 for 18 months)
The share price was at around .45 yesterday and gapped up to the .55 area today
What are the most likley reasons the share price goes up on this news?
Is it possible they drive it up to short (covering with their .33 cent shares) or is it just a positive reaction to funding
Thanks and excuse any ignorance
David

Q: GUD has started its crescendo. How long, in your expectation, for Goodman to repeat his Paladin act ? The chap is almost on a mission, and exudes confidence. Even his own father is in awe.
Rightly so, I believe.

Q: Hi, I've noticed quite good increases in Concordia lately. I still (blush) have a lot of these shares. Any news? thks Gord

Q: Hi
I still have some shares in PHM. What does the proposed split of the company mean for stock owners in PHM ?
Is there any chance that there could be recovery of stock value?
Kathy

Q: I realize that I have a poor understanding of how to value "pre-sales" biotech companies such as TR. How is a quantitative value placed on them - I assume it is based somehow on the potential market share of the company in the specific area they are developing drugs for, as well as the size of that market and the risk of getting product to commercial trade. But this seems all very subjective. For example, TRIL has traded all over the map, the value can seem to double or be cut in half based on some combination of risk profile vs. potential. For the average retail investor, how does one go about trying to value these companies, or is is better to wait until sales start to happen and then try to value to company on sales projection? Other examples could be PLI, or one I'm still trying to forget from years past, ISA. I'm wondering if these types of companies have a place in a responsible portfolio even one is "high growth" oriented?

Q: New report soon on GUD ?

Q: Hi folks,almost to embaressed to admit still own some Concordia,but company issued n/r:Concordia International Corp. Makes Final Earn Out Payment to Cinven,Today's payment of £72 million, plus interest of approximately £1.5 million, was paid with cash on hand.But a poster stated,"Had to raise 9.5% 1st lien bonds to pay the earn out. Hardly a good sign.". Could I please get your opinion on todays news and future of company going forward, at least Trump yesterday seemed to throw an olive branch at pharma companies that he would work with them and not bury them. Thanks as always, jb

Q: made another repayment to cinven today from cash on hand. any comments please.

Q: Could I get your thoughts on Centric Health Corp. It is a small healthcare company and has had a big run up recently, I was thinking of initiating a 1/2 position. Thanks.

Q: Trillium continues to drop even after the end of tax-loss season. I'm second guessing that this has long term potential - I thought the explanation of the effacy vs. toxicity profile was good last month and expected the stock to be stronger. What are your thoughts?

Q: I wonder if you would provide me with your analysis of PHM's year end financials released today. Thanks.

Francesco

Q: What's the outlook for this company in the next two years? Thanks.

Q: Do you have an opinion on this ETF? It has a yield of 8.8%, utilizing a coverd call strategy.

Q: Now that PLI has received orphan drug designation for PBI-4050, what is the liklihood the stock will rise to $4.75 as predicted? If it does reach that level, is that a take-off point to much higher levels?
Elmer

Q: Hi Peter, What is your analysis of Valeant? I went through the conference call and recent presentation and it sounds they are on track to pay down $5B in next 12 months. Is market panicking?